# Hiroyuki Murai

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hiroyuki-murai/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,328 |
| Field | Myasthenia Gravis and Thymoma |
| h-index | 45 |
| i10-index | 116 |
| Last Known Institution | International University of Health and Welfare |
| OpenAlex ID | https://openalex.org/A5077281690 |
| ORCID iD | 0000-0003-1612-1440 |
| Works | 329 |

## Researcher papers

- [International consensus guidance for management of myasthenia gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis/)
- [Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study](https://scholariq.org/papers/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody/)
- [International Consensus Guidance for Management of Myasthenia Gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis-2/)
- [Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-efficacy-and-tolerability-of-efgartigimod-in-patients-with-generalised/)
- [Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis](https://scholariq.org/papers/intrathecal-activation-of-the-il-17-il-8-axis-in-opticospinal-multiple-sclerosis/)
- [Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease](https://scholariq.org/papers/intracellular-a-42-activates-p53-promoter-a-pathway-to-neurodegeneration-in/)
- [Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/safety-and-efficacy-of-zilucoplan-in-patients-with-generalised-myasthenia-gravis/)
- [Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis](https://scholariq.org/papers/long-term-safety-and-efficacy-of-eculizumab-in-generalized-myasthenia-gravis/)
- [Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis](https://scholariq.org/papers/characteristic-cerebrospinal-fluid-cytokine-chemokine-profiles-in-neuromyelitis/)
- [Characterization of IgG4 anti‐neurofascin 155 antibody‐positive polyneuropathy](https://scholariq.org/papers/characterization-of-igg4-anti-neurofascin-155-antibody-positive-polyneuropathy/)
- [Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan](https://scholariq.org/papers/real-world-safety-profile-of-eculizumab-in-patients-with-paroxysmal-nocturnal/)

## Researcher topics

- [Myasthenia Gravis and Thymoma](https://scholariq.org/topics/myasthenia-gravis-and-thymoma/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Parkinson's Disease and Spinal Disorders](https://scholariq.org/topics/parkinson-s-disease-and-spinal-disorders/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [International University of Health and Welfare](https://scholariq.org/institutions/international-university-of-health-and-welfare/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.